NASDAQ
24.03.26 | 20:52
1,660 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 13:36 | BeyondSpring, Inc.: BeyondSpring Reports 2025 Year-End Financial Results | 39 | GlobeNewswire (Europe) | Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care... ► Artikel lesen | |
| 13:30 | BeyondSpring Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.25 | BeyondSpring Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.12.25 | BeyondSpring-Aktie steigt nach positiven Daten aus Lungenkrebsstudie in Asien | 2 | Investing.com Deutsch | ||
| 12.12.25 | BeyondSpring reports positive Asian subset data for lung cancer drug | 1 | Investing.com | ||
| 12.12.25 | BeyondSpring, Inc.: BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration ... | 1 | GlobeNewswire (USA) | ||
| 11.12.25 | BeyondSpring, Inc.: BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC | 379 | GlobeNewswire (Europe) | In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin... ► Artikel lesen | |
| 21.11.25 | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | BeyondSpring Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11.25 | BeyondSpring GAAP EPS of -$0.05 | 1 | Seeking Alpha | ||
| 12.11.25 | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.05.25 | BeyondSpring, Inc.: BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update | 279 | GlobeNewswire (Europe) | Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapySEED's first-in-class RBM39 degrader, reported... ► Artikel lesen | |
| 27.03.25 | BeyondSpring, Inc.: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones | 287 | GlobeNewswire (Europe) | Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,835 | +1,07 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,860 | -12,97 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| MAZE THERAPEUTICS | 34,270 | -29,89 % | Leerink reiterates Maze Therapeutics stock rating on trial data | ||
| BIONTECH | 76,65 | +1,93 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| EVOTEC | 4,353 | +5,68 % | Evotec meldet klinischen Durchbruch mit BMS: Phase-1-Start bei "Molecular Glue" - 10 Mio. Dollar Meilenstein fließen | Evotec bekommt in der heiß umkämpften Onkologie-Pipeline einen echten Aufmerksamkeitsschub: Partner Bristol Myers Squibb (BMS) hat eine Phase-1-Studie für den CELMoD-Wirkstoff BMS-986506 gestartet.... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,78 | +13,43 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TYRA BIOSCIENCES | 37,980 | +4,43 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,240 | +1,21 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 26,755 | -0,06 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| NANOBIOTIX | 27,200 | +5,84 % | Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up | ||
| ENLIVEN THERAPEUTICS | 35,140 | +12,81 % | Clear Street reiterates Enliven Therapeutics stock Buy on CML opportunity | ||
| VALNEVA | 2,822 | -2,08 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| ARCELLX | 114,51 | -0,13 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| NUVALENT | 100,28 | +4,36 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,890 | +5,58 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen |
BEYONDSPRING INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,660 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.